Citigroup analyst Yigal Nochomovitz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $208 to $127.
Reported Late Monday Feb 6, Thoughtworks Acquires Leading Australian AWS Consultancy, Itoc; No Financial Terms Disclosed
Thoughtworks (NASDAQ:TWKS), a global technology consultancy that integrates strategy, design and engineering, today announced its acquisition of privately-held Itoc, a leading Amazon Web Services (AWS) Advanced
